77 related articles for article (PubMed ID: 37749034)
21. Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives.
Lin N; Song Y; Zhu J
Chin J Cancer Res; 2020 Jun; 32(3):303-318. PubMed ID: 32694896
[TBL] [Abstract][Full Text] [Related]
22. Case report: Sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin's disease developing resistance to pembrolizumab.
Reuthner K; Aubele P; Menhart K; Rath P; Harrer DC; Herr W; Hahn J; Vogelhuber M; Heudobler D; Lueke F; Reichle A; Grube M
Front Pharmacol; 2024; 15():1334233. PubMed ID: 38444946
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 Inhibitor for Advanced Urothelial Cancer: A Case-Series Study.
Zhao H; Xu Z; Li C; Xu T; Zhang J; Jiao J; Yang B; Qin R; Yang L; Qin W; Jing Y
Adv Ther; 2024 Feb; 41(2):857-866. PubMed ID: 38048019
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and Safety of Pembrolizumab in Recurrent and Relapsed Classic Hodgkin Lymphoma: A Systematic Review.
Hossain MF; Kharel M; Akter M; Parajuli B; Yadav I; Mandal N; Mandal A; Aziz SN
Cureus; 2023 Sep; 15(9):e46032. PubMed ID: 37900494
[TBL] [Abstract][Full Text] [Related]
25. Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin's lymphoma: A prospective study of 46 cases.
Wu H; Zhao C; Gu K; Jiao Y; Hao J; Sun G
Mol Clin Oncol; 2014 Sep; 2(5):695-700. PubMed ID: 25054032
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy and safety analysis of a combination regimen with BCL-2 inhibitor in relapsed/refractory primary systemic light chain amyloidosis with t(11;14) from a single center].
Zhai AL; Liu Y; Peng N; Gong LZ; Dou XL; Wen L; Lu J
Zhonghua Nei Ke Za Zhi; 2023 Nov; 62(11):1323-1328. PubMed ID: 37935499
[No Abstract] [Full Text] [Related]
27. Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group.
Daw S; Hasenclever D; Mascarin M; Fernández-Teijeiro A; Balwierz W; Beishuizen A; Burnelli R; Cepelova M; Claviez A; Dieckmann K; Landman-Parker J; Kluge R; Körholz D; Mauz-Körholz C; Wallace WH; Leblanc T
Hemasphere; 2020 Feb; 4(1):e329. PubMed ID: 32072145
[TBL] [Abstract][Full Text] [Related]
28. Evaluating the impact of PD-1 inhibitor treatment on key health outcomes for cancer patients in China.
Zhang P; Zhang L; Xu K; Lin Y; Ma R; Zhang M; Li X
Int J Clin Pharm; 2024 Apr; 46(2):429-438. PubMed ID: 38165516
[TBL] [Abstract][Full Text] [Related]
29. Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report.
Zheng Y; Xue YY; Zhao YQ; Chen Y; Li ZP
Front Immunol; 2023; 14():1254812. PubMed ID: 37901233
[TBL] [Abstract][Full Text] [Related]
30. Managing common toxicities associated with checkpoint inhibitor and chemotherapy combinations for untreated classic Hodgkin lymphoma.
Kuczmarski TM; Lynch RC
Br J Haematol; 2024 May; ():. PubMed ID: 38698683
[TBL] [Abstract][Full Text] [Related]
31. Long-term complete response to anti-programmed-death-1 monotherapy in a patient with relapsed and refractory ovarian adenocarcinoma: A case report.
Zhou GD; Li Q
World J Clin Cases; 2024 Apr; 12(11):1967-1973. PubMed ID: 38660551
[TBL] [Abstract][Full Text] [Related]
32. Incidental improvement of programmed cell death-1 receptor inhibitor-induced vitiligo after initiation of dupilumab therapy for refractory pruritus.
Robinson W; McLellan BN
JAAD Case Rep; 2023 Dec; 42():31-34. PubMed ID: 37965187
[No Abstract] [Full Text] [Related]
33. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
[TBL] [Abstract][Full Text] [Related]
34. High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy.
Rauf MS; Maghfoor I; Elhassan TA; Akhtar S
Med Oncol; 2015 Jan; 32(1):388. PubMed ID: 25429839
[TBL] [Abstract][Full Text] [Related]
35. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
Goldkuhle M; Dimaki M; Gartlehner G; Monsef I; Dahm P; Glossmann JP; Engert A; von Tresckow B; Skoetz N
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012556. PubMed ID: 30001476
[TBL] [Abstract][Full Text] [Related]
36. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.
Vardhana S; Cicero K; Velez MJ; Moskowitz CH
Oncologist; 2019 Jan; 24(1):86-95. PubMed ID: 30082490
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy and safety of programmed death-1 inhibitor in the treatment of relapsed/refractory classical Hodgkin's lymphoma].
Shan DD; Liu HM; Liu W; Huang WY; Lyu R; Deng SH; Yi SH; An G; Xu Y; Sui WW; Wang TY; Fu MW; Zhao YZ; Qiu LG; Zou DH
Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):555-560. PubMed ID: 37749034
[No Abstract] [Full Text] [Related]
38. Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma.
Casadei B; Argnani L; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Cavo M; Zinzani PL
Cancer Med; 2020 Nov; 9(21):7830-7836. PubMed ID: 32881376
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
